172 related articles for article (PubMed ID: 24023332)
1. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer.
Neki K; Kawahara H; Watanabe K; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Apr; 33(4):1769-72. PubMed ID: 23564832
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Oki E; Emi Y; Miyamoto Y; Kabashima A; Higashi H; Ogata Y; Ikebe M; Saeki H; Tokunaga S; Shirabe K; Beppu T; Uchida S; Takatsuki M; Sakoda M; Eguchi S; Akagi Y; Kakeji Y; Baba H; Natsugoe S; Maehara Y;
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1067-74. PubMed ID: 26334293
[TBL] [Abstract][Full Text] [Related]
6. [A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
Takeuchi M; Ogata Y; Ishibashi N; Uchida S; Murakami N; Kibe S; Takahashi K; Yahara T; Shirouzu K
Gan To Kagaku Ryoho; 2012 May; 39(5):843-6. PubMed ID: 22584346
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
Mukai T; Uehara K; Goto H; Hiramatsu K; Kobayashi S; Sakamoto E; Maeda A; Takeuchi E; Okada Y; Ebata T; Nagino M;
Jpn J Clin Oncol; 2017 Jul; 47(7):597-603. PubMed ID: 28398493
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
[TBL] [Abstract][Full Text] [Related]
10. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
[TBL] [Abstract][Full Text] [Related]
11. Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
Ogawa M; Anan T; Suzuki T; Okuma M; Ichihara K; Hasegawa T; Yoshida K; Yanaga K
Anticancer Res; 2016 May; 36(5):2505-11. PubMed ID: 27127165
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
Morimoto T; Yata Y; Yonenaga Y; Hanaki K; Mise M; Higaside S; Kanda Y; Noda H
Gan To Kagaku Ryoho; 2015 Jun; 42(6):743-5. PubMed ID: 26199249
[TBL] [Abstract][Full Text] [Related]
13. [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Maruo H; Suzuki K; Ishikawa S; Murakami T; Higashi Y; Shoji T; Yamazaki M; Taniguchi M; Nishiyama R
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2583-6. PubMed ID: 25596052
[TBL] [Abstract][Full Text] [Related]
14. Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.
Kabashima A; Kimura K; Sanefuji K; Maekawa S
Fukuoka Igaku Zasshi; 2017 Jan; 108(1):8-13. PubMed ID: 29226661
[TBL] [Abstract][Full Text] [Related]
15. Consequences of chemotherapy on resection of colorectal liver metastases.
Pessaux P; Chenard MP; Bachellier P; Jaeck D
J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
[TBL] [Abstract][Full Text] [Related]
16. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
18. Portal venous gas following chemotherapy for colorectal cancer liver metastasis.
Zalinski S; Scatton O; Jacqmin S; Tacher V; Brézault C; Soubrane O
Eur J Surg Oncol; 2009 May; 35(5):557-60. PubMed ID: 18950980
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Synchronous Liver Metastasis of Ascending Colon Cancer with Pathological Complete Response to S-1/Oxaliplatin (SOX) and Bevacizumab].
Tago T; Suzuki K; Nishida K; Maruyama T; Shimazaki J; Shimoda M; Suzuki S; Kou K; Morishita Y
Gan To Kagaku Ryoho; 2018 May; 45(5):871-874. PubMed ID: 30026455
[TBL] [Abstract][Full Text] [Related]
20. [A Case Report of SOX Treatment for Primary Duodenal Carcinoma with Liver Metastasis].
Yokota Y; Nagase H; Noguchi K; Hamabe A; Hirota M; Oshima K; Tanida T; Tomimaru Y; Kawase T; Morita S; Imamura H; Iwazawa T; Akagi K; Dono K
Gan To Kagaku Ryoho; 2018 Apr; 45(4):715-717. PubMed ID: 29650845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
